GlobeNewswire Inc.··Pomerantz LlpGossamer Bio Stock Crashes 80% After Failed Drug Trial, Triggering Securities Probe
Pomerantz LLP investigates Gossamer Bio after seralutinib Phase 3 trial failure triggers 80% stock crash, raising securities fraud concerns.
ALITCCGOSSsecurities fraudclass action lawsuit